ERBB2 and breast cancer: These agents are recommended for prescribing by the NCCN (National Comprehensive Cancer Network) Breast Cancer Treatment Guidelines [2], along with anti-HER2 therapies for HER2+ (human epidermal growth factor 2)-positive disease.